Expression and prognosis analysis of in human cancers.

: JumonjiC (JmjC) domain-containing protein 5 () plays an important part in cancer metabolism. However, the prognostic value of in most human cancers is unknown yet. We aimed to examine the expression level and prognostic value of , immune cell infiltration in cancer patients, and simultaneously to examine the correlations among them. : The mRNA and protein expression of were analyzed through online Tumor Immune Estimation Resource (TIMER) or immunohistochemistry (IHC) of tissue microarray sections (TMAs) in cancer versus normal tissues. The Kaplan-Meier Plotter databases were used to assess the prognostic values. The connection between the expression of and the abundances of six infiltrating immune cells were explored by TIMER in breast cancer (BRCA), liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD) and stomach adenocarcinoma (STAD). We used the Cox proportional hazards model to investigate the correlations among clinical outcome, the abundance of immune cell infiltration and expression. : We found that the expression was obviously lower in BRCA, LIHC and lung cancer (LUC) but higher in STAD than in normal tissues. High expression of had a better prognosis only in BRCA, LIHC and LUC but a worse prognosis in STAD. The expression of has a significant connection with the abundance of six kind of infiltrating immune cells. The expression of plus the number of immune-infiltrating B cells or macrophages may jointly serve as a prognostic marker in the above four cancers. : We provided novel evidence of as an essential prognostic biomarker and perspective therapeutic target in BRCA, LUAD, LIHC and STAD.